1. In Vivo
  2. >>Innovation

Patient-Specificity Meets Digital Ecosystems As Corin Acquires TKR Robotics Player Omni

 
• By Ashley Yeo

Hip and knee replacement challenger firm Corin Group has a big ambition to revolutionize orthopedics with connected digital ecosystems and patient-specific concepts. That aim has come a step closer with its acquisition of robotic-assisted total knee replacement (TKR) company Omni Orthopaedics. Corin's Elvio Gramignano believes this approach will lead to real change in health care delivery.       

Business merger
• Source: Shutterstock

The private equity-backed hip and knee implant company, Corin Group PLC, has taken its patient-centered, value-based strategy to another level, with the purchase of Omni Orthopaedics Inc. The US-based company specializes in robotic-assisted total knee replacement (TKR), using its OmniBotics robot, OmniBot cutting guide and BalanceBot tool to measure ligament function.

The transaction value was not disclosed, but it is Corin’s biggest acquisition to date, and a “pivotal” buy, the company’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Future Proofing Gene Therapy Assays For Regulatory Success

 
• By Deborah Phippard

As gene therapy advances and regulations tighten, biopharma companies face growing pressure to design diagnostic assays that are both flexible and future ready. Strategic early investment in assay development can prevent costly delays and rework as therapies progress toward approval.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

IMMA Starts A Silent Revolution By Making IVF Journey Digital, Predictable And At Home

 
• By Ashley Yeo

IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

More from In Vivo

video
Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.